BlackRock, Inc. 13D and 13G filings for Ultragenyx Pharmaceutical Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-01-29 3:26 pm Purchase |
2023-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
BLACKROCK INC BLK |
5,238,400 6.400% |
901,908 (+20.80%) |
Filing |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
BLACKROCK INC BLK |
4,336,492 6.200% |
925,078 (+27.12%) |
Filing |
| 2022-03-09 5:18 pm Sale |
2022-02-28 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
BLACKROCK INC BLK |
3,411,414 4.900% |
-73,238 (-2.10%) |
Filing |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
BLACKROCK INC BLK |
3,484,652 5.100% |
-1,802,824 (-34.10%) |
Filing |
| 2021-02-01 08:30 am Purchase |
2020-12-31 | 13G | Ultragenyx Pharmaceutical Inc. RARE |
BLACKROCK INC BLK |
5,287,476 8.000% |
554,392 (+11.71%) |
Filing |